AstraZeneca Plc (AZN.L, AZN) said Friday that results from the global Phase II Study 22 trial testing the company's tremelimumab added to IMFINZI (durvalumab) demonstrated promising clinical activity and tolerability in patients with advanced hepatocellular carcinoma or HCC.
from RTT - Biotech https://ift.tt/3gDuqVw
via IFTTT
No comments:
Post a Comment